PTC Therapeutics, Inc. Repayments of Secured Debt
PTC Therapeutics, Inc. (PTCT) reported Repayments of Secured Debt of $300.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfSecuredDebt · last filed 2026-02-19
- PTC Therapeutics, Inc. repayments of secured debt for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- PTC Therapeutics, Inc. repayments of secured debt for the quarter ending 2020-09-30 was $18.33M, a 266.66% increase year-over-year.
- PTC Therapeutics, Inc. repayments of secured debt for the quarter ending 2020-06-30 was $5.00M, a 199.94% increase year-over-year.
- PTC Therapeutics, Inc. repayments of secured debt for the quarter ending 2020-03-31 was $5.00M.
- PTC Therapeutics, Inc. repayments of secured debt for fiscal 2023 was $300.00M.
- PTC Therapeutics, Inc. repayments of secured debt for fiscal 2020 was $28.33M, a 142.85% increase from fiscal 2019.
- PTC Therapeutics, Inc. repayments of secured debt for fiscal 2019 was $11.67M.
- PTC Therapeutics, Inc. repayments of secured debt for fiscal 2018 was $0.00.
| Period end | Repayments of Secured Debt 3 month | Repayments of Secured Debt 6 month | Repayments of Secured Debt 9 month | Repayments of Secured Debt 12 month |
|---|---|---|---|---|
| 2023-12-31 | $300.00M 10-K · filed 2026-02-19 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $18.33M derived: sum of 2 quarters · filed 2022-02-22 | $23.33M derived: sum of 3 quarters · filed 2022-02-22 | $28.33M 10-K · filed 2022-02-22 |
| 2020-09-30 | $18.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $23.33M derived: sum of 2 quarters · filed 2021-10-28 | $28.33M 10-Q · filed 2021-10-28 | $33.33M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $10.00M 10-Q · filed 2021-07-29 | $15.00M derived: sum of 3 quarters · filed 2022-02-22 | $20.00M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $5.00M 10-Q · filed 2021-05-04 | $10.00M derived: sum of 2 quarters · filed 2022-02-22 | $15.00M derived: sum of 3 quarters · filed 2022-02-22 | $16.67M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $10.00M derived: sum of 2 quarters · filed 2022-02-22 | $11.67M derived: sum of 3 quarters · filed 2022-02-22 | $11.67M 10-K · filed 2022-02-22 |
| 2019-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $6.67M derived: sum of 2 quarters · filed 2020-10-29 | $6.67M 10-Q · filed 2020-10-29 | $6.67M derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.67M 10-Q · filed 2020-08-05 | $1.67M derived: sum of 3 quarters · filed 2020-08-05 | |
| 2019-03-31 | $0.00 10-Q · filed 2020-04-30 | $0.00 derived: sum of 2 quarters · filed 2020-04-30 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-10-30 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |